Literature DB >> 17932316

Heritability of clot formation, morphology, and lysis: the EuroCLOT study.

Angela M Carter1, Charlotte M Cymbalista, Tim D Spector, Peter J Grant.   

Abstract

OBJECTIVE: The relative balance between clot formation and fibrinolysis is considered to reflect thrombotic potential following vascular injury. The aims of the present study were to (1) to determine the contribution of genetic and environmental factors to variance in measures of clot structure/function in the Leeds Family Study, and (2) to determine the relationship between measures of clot structure/function and cardiovascular risk. METHODS AND
RESULTS: Using high throughput turbidimetric assays, heritabilities of measures of clot formation, clot structure, and clot lysis were approximately 0.30. Fibrinogen contributed to variance in all measures and plasminogen activator inhibitor-1 to variance in lysis variables. Subjects at increased cardiovascular risk due to the presence of the metabolic syndrome (MetS) had increased clot density (MaxAbs(C): 0.358 [0.340, 0.375]au) and prolonged lysis times (Lys(T): 510 [6569, 7939]s) compared with those without MetS (MaxAbs(C): 0.319 [0.310, 0.328]au, P=0.003; Lys(T): 7221 [4884, 5328]s, P<0.001). Furthermore, measures of clot structure/function increased progressively with increasing number of MetS components.
CONCLUSIONS: This study indicates that genetic factors contribute modestly to variance in clot structure/function and that clot structure/function is related to presence of the MetS and number of MetS components. Identification of the genetic and environmental factors influencing clot structure/function may further our understanding of the underlying factors predisposing to cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17932316     DOI: 10.1161/ATVBAHA.107.153221

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  33 in total

1.  Insulin resistance and cardiovascular risk marker evaluation in morbid obesity 12 months after bariatric surgery compared to weight-matched controls.

Authors:  Alison J Dawson; Thozhukat Sathyapalan; Peter Sedman; Ramzi Ajjan; Eric S Kilpatrick; Stephen L Atkin
Journal:  Obes Surg       Date:  2014-03       Impact factor: 4.129

2.  Beneficial effect of cigarette smoking cessation on fibrin clot properties.

Authors:  Ewa Stępień; Tomasz Miszalski-Jamka; Przemysław Kapusta; Grzegorz Tylko; Mieczysław Pasowicz
Journal:  J Thromb Thrombolysis       Date:  2011-08       Impact factor: 2.300

3.  Genome scan of clot lysis time and its association with thrombosis in a protein C-deficient kindred.

Authors:  M E Meltzer; S J Hasstedt; C Y Vossen; P W Callas; Ph G DE Groot; F R Rosendaal; T Lisman; E G Bovill
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

4.  Assessment of hemostatic disturbances in women with established rheumatoid arthritis.

Authors:  Aleksandra Vranic; Iva Pruner; Mirjana Veselinovic; Nida Soutari; Anica Petkovic; Vladimir Jakovljevic; Aleksandra Antovic
Journal:  Clin Rheumatol       Date:  2019-06-17       Impact factor: 2.980

Review 5.  Not all clots are created equal: a review of deficient thrombolysis with tissue plasminogen activator (tPA) in patients with metabolic syndrome.

Authors:  Charles I Mosimah; Pamela J Murray; James W Simpkins
Journal:  Int J Neurosci       Date:  2018-12-27       Impact factor: 2.292

6.  FXIII-A Leu34 genetic variant in premature coronary artery disease: a genotype--phenotype case control study.

Authors:  Johanne Silvain; Ana Pena; Jean-Baptiste Vignalou; Jean-Sébastien Hulot; Sophie Galier; Guillaume Cayla; Anne Bellemain-Appaix; Olivier Barthélémy; Farzin Beygui; Claire Bal-dit-Sollier; Ludovic Drouet; John W Weisel; Gilles Montalescot; Jean-Phillippe Collet
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

7.  Alteration of blood clotting and lung damage by protamine are avoided using the heparin and polyphosphate inhibitor UHRA.

Authors:  Manu Thomas Kalathottukaren; Libin Abraham; Piyushkumar R Kapopara; Benjamin F L Lai; Rajesh A Shenoi; Federico I Rosell; Edward M Conway; Edward L G Pryzdial; James H Morrissey; Charles A Haynes; Jayachandran N Kizhakkedathu
Journal:  Blood       Date:  2016-12-29       Impact factor: 22.113

8.  Clot Structure: A Potent Mortality Risk Factor in Patients on Hemodialysis.

Authors:  Katharina Schuett; Anna Savvaidis; Sebastian Maxeiner; Katharina Lysaja; Vera Jankowski; Stephan H Schirmer; Nada Dimkovic; Peter Boor; Nadine Kaesler; Friedo W Dekker; Jürgen Floege; Nikolaus Marx; Georg Schlieper
Journal:  J Am Soc Nephrol       Date:  2017-01-05       Impact factor: 10.121

9.  2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2010-07       Impact factor: 19.112

10.  Identification of quantitative trait loci for fibrin clot phenotypes: the EuroCLOT study.

Authors:  Frances M K Williams; Angela M Carter; Bernet Kato; Mario Falchi; Lise Bathum; Gabriela Surdulescu; Kirsten Ohm Kyvik; Aarno Palotie; Tim D Spector; Peter J Grant
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-01-15       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.